Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Change in Receivables (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 3 years of Change in Receivables data on record, last reported at -$5.0 million in Q1 2025.

  • For Q1 2025, Change in Receivables changed N/A year-over-year to -$5.0 million; the TTM value through Dec 2024 reached $5.0 million, changed N/A, while the annual FY2024 figure was $5.0 million, N/A changed from the prior year.
  • Change in Receivables reached -$5.0 million in Q1 2025 per ZNTL's latest filing, down from $5.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $5.0 million in Q4 2024 and bottomed at -$5.0 million in Q1 2025.
  • Average Change in Receivables over 3 years is $1333.3, with a median of $4000.0 recorded in 2022.